Nikolay Delev

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial

Eric F. Morand, Marilyn C. Pike, Joan T. Merrill et al. · Arthritis & Rheumatology · 2022 · 248 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)

Peter Nash, Kamal Ohson, Jessica A. Walsh et al. · Annals of the Rheumatic Diseases · 2018 · 88 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16

Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis

Arthur Kavanaugh, Dafna D. Gladman, Christopher J Edwards et al. · Arthritis Research & Therapy · 2019 · 79 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies

Dafna D. Gladman, Arthur Kavanaugh, Juan J. Gómez‐Reino et al. · RMD Open · 2018 · 38 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14

Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study

Richard Furie, Douglas R. Hough, Allison Gaudy et al. · Lupus Science & Medicine · 2022 · 36 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16